In vivo performance of a drug-eluting contact lens to treat glaucoma for a month
In vivo performance of a drug-eluting contact lens to treat glaucoma for a month
复制标题
DOI：
10.1016/j.biomaterials.2013.09.032
复制
发表时间：
2014-01-01
期刊：
影响因子：
14
通讯作者：
Kohane, Daniel S.
中科院分区：
文献类型：
--
作者：
Ciolino, Joseph B.;Stefanescu, Cristina F.;Kohane, Daniel S.
近半个世纪以来，隐形眼镜一直被认为是眼部药物输送的一种手段，但如何控制药物释放一直是一个重大挑战。我们开发了一种药物洗脱隐形眼镜，设计用于延长拉坦前列素的输送，用于治疗青光眼，青光眼是全球不可逆失明的主要原因。采用紫外光聚合的方法，将latanoprod -聚乳酸-羟基乙酸膜包埋在甲基萘菲康中，制备了latanoprod -洗脱隐形眼镜。体外和体内研究表明，药物释放早期爆发，随后持续释放一个月。含有较厚药物聚合物薄膜的隐形眼镜在初次破裂后释放出更多的药物。在体内，单只隐形眼镜能够在至少一个月的时间内，使房水中的拉坦前列素浓度与局部拉坦前列素溶液（目前青光眼的一线治疗方法）的浓度相当。这种晶体在细胞培养和动物实验中都是安全的。这种隐形眼镜设计可以潜在地用于青光眼的治疗，并作为其他眼部药物输送应用的平台。(C) 2013 Elsevier Ltd.版权所有。
For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery, but achieving controlled drug release has been a significant challenge. We have developed a drug-eluting contact lens designed for prolonged delivery of latanoprost for the treatment of glaucoma, the leading cause of irreversible blindness worldwide. Latanoprost-eluting contact lenses were created by encapsulating latanoprost-poly(lactic-co-glycolic acid) films in methafilcon by ultraviolet light polymerization. In vitro and in vivo studies showed an early burst of drug release followed by sustained release for one month. Contact lenses containing thicker drug-polymer films demonstrated released a greater amount of drug after the initial burst. In vivo, single contact lenses were able to achieve, for at least one month, latanoprost concentrations in the aqueous humor that were comparable to those achieved with topical latanoprost solution, the current first-line treatment for glaucoma. The lenses appeared safe in cell culture and animal studies. This contact lens design can potentially be used as a treatment for glaucoma and as a platform for other ocular drug delivery applications. (C) 2013 Elsevier Ltd. All rights reserved.